HIV drug weight gain mystery: healthy volunteers sought for clues
NCT ID NCT05652478
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 58 times
Summary
This study tests four different HIV drug regimens in 120 healthy volunteers to see how they affect metabolism and weight. Participants take one of the drugs or a combination for four weeks, with blood tests, body scans, and optional fat biopsies. The goal is to understand why some HIV drugs cause weight gain, which could lead to better treatments for people with HIV.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dolutegravir and Tenofovir alafenamide (HIV drugs)
- What this could lead to
- If successful, this study could help explain why some HIV drugs cause weight gain, leading to safer treatments for people with HIV.
- What could go wrong
- This is an early phase 2 study in healthy volunteers, not people with HIV, so results may not directly apply. The study is small and short-term, so long-term effects remain unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Aged 18 to 55 years. * Able to provide informed consent. * Willing to allow samples and data to be stored and shared for future research. * Agrees to use a barrier method of contraception or abstain from sexual activity starting at screening though the end of study participation. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Current infection with HIV or hepatitis A, B, or C. * Body mass index (BMI) \<18.5 kg/m\^2 or \>30.0 kg/m\^2. * Weight change \>5% in the past 6 months. * History of or current cardiovascular disease such as congestive heart failure, heart block, or clinically relevant abnormal ECG as determined by investigators. * History of or current liver disease or alanine transaminase serum level \>2x upper limit of normal. * History of or current kidney disease or renal insufficiency, or estimated creatinine clearance \<=80 mL/min (Modification of Diet in Renal Disease equation). * Current cancer or history of cancer within 5 years of screening, with the exception of squamous cell carcinoma or basal cell carcinoma that is localized and does not require systemic therapy. * History of bariatric surgery. * Diabetes mellitus as defined by a prior diagnosis or a hemoglobin A1c of \>6.4 percent on screening labs. * Fasting serum glucose \>126 mg/dL. * History of or current hypo- or hyper-thyroid or abnormal TSH, except minor deviations deemed to be of no clinical significance by the investigator. * History of chronic obstructive pulmonary disease. * Psychological conditions by self-report, such as (but not limited to) clinical depression, or bipolar disorders, which would be incompatible with safe and successful participation in this study. * Pregnancy or within 1 year post-partum. * Breastfeeding. * Blood pressure \>140/90 mm Hg or current antihypertensive therapy. * Hemoglobin that is either 10 percent below the lower limit or 10 percent above the upper limit of the normal range for the Clinical Center Laboratory (acceptable ranges: females 10.08-17.27 g/dL, males 12.33-19.25 g/dL). * History of illicit drug, opioid, or alcohol abuse within the last 5 years; current use of illicit drugs or opioids (by history) or excessive alcohol (CAGE assessment score \>=2). * Current use of the following prescription or over-the-counter medications and supplements: * Carbamazepine * Oxcarbazepine * Phenobarbital * Phenytoin * Primidone * Rifabutin * Rifampin * Rifapentine * St. John's wort (Hypericum perforatum) * Cation-containing antacids or laxatives * Sucralfate * Buffered medications * Oral calcium, iron, magnesium, or zinc supplements, including multivitamins containing these polyvalent cations * Dalfampridine * Metformin * Dofetilide * Thyroid medications * Corticosteroids * Weight loss medications, including prescription drugs (eg, semaglutide and tirzepatide) and over-the-counter diet pills * Use of TAF, TDF, and/or FTC for the purpose of HIV PrEP or in a research study within the past 6 months. * Any history of exposure to cabotegravir or lenacapavir (eg, as HIV PrEP or as a participant in a research study for these drugs). * Current use of prescription or nonprescriptive medications that may have interactions with study drugs or confound the study measurements as determined by the investigators. * History of adverse or allergic reactions to the study drugs. * Daily caffeine intake \>500 mg (about 4 cups of coffee). * Current smoker or user of tobacco products. * A change in the participant's diet and/or exercise regimen in the past 3 months or during the timeframe of the study period that, in the opinion of the investigator, would compromise the integrity of the data. * High-risk sexual activity as determined by the investigators, and/or inability or unwillingness to use barrier contraception during the protocol. * Any other condition, medication, or dietary pattern that, in the opinion of the investigators, increases risk to the participant, prevents the participant from complying with study procedures, prevents the participant from completing the study, or interferes with the interpretation of study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental brain drug TAK-935 put to the test in healthy volunteers
- Can a phone app help pregnant women manage weight gain?
- Tracing a Low-THC cannabis extract through the human body
- Can a new injection SGB-9768 pass its first safety test?
- Can a new PET tracer reveal the Body's hidden stress?
- Zapping the brain to shift Decision-Making in depression and aging